Form 4: Orchestra BioMed CEO's RSU Tax Withholding

Orchestra BioMed Holdings, Inc. CEO David P. Hochman reported a routine disposition of shares to cover tax obligations related to restricted stock unit vesting.

Summary

• David P. Hochman, CEO and Chairperson of Orchestra BioMed Holdings, Inc., reported a transaction on December 10, 2025.
• The transaction involved the disposition of 40,355 shares of Common Stock directly and 3,283 shares indirectly through the DPH 2008 Trust.
• These shares, totaling 43,638, were withheld by the Issuer at a price of $4.67 per share to satisfy tax withholding obligations.
• The disposition was in connection with the vesting of restricted stock units (RSUs).
• No shares were sold in the open market as a result of this transaction.
• Following the transaction, Mr. Hochman beneficially owns 572,467 shares directly and 448,622 shares indirectly through various trusts.

Sentiment

Score: 5

Explanation: The filing reports a routine, expected transaction related to executive compensation (RSU vesting and tax withholding). It is neutral in sentiment as it reflects a standard operational aspect of equity compensation rather than a strategic or performance-related event.

Positives

• The transaction is a routine tax withholding event, indicating the vesting of restricted stock units for the CEO, which is a common form of executive compensation.
• No shares were sold in the open market, suggesting no direct market selling pressure from this specific event.

Negatives

• The disposition of shares, even for tax purposes, reduces the direct and indirect beneficial ownership of the reporting person.

Future Outlook

NA

Industry Context

This is a routine insider transaction filing (Form 4) related to executive compensation, specifically restricted stock unit vesting and associated tax withholding. It does not provide broader industry context or trends.

Related Party Transactions

• The disposition of shares for tax withholding involved indirect ownership through the DPH 2008 Trust, Solomon Ascher Hochman 2019 Trust, Hannah Hochman 2019 Trust, Judah Herman Hochman 2019 Trust, and NSH 2008 Family Trust, which are related parties to David P. Hochman.

Stakeholder Impact

• Shareholders: The transaction is a routine tax withholding event and does not indicate a change in the company's operational or financial performance. It slightly reduces the beneficial ownership of a key executive, but no shares were sold into the open market.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary transaction where shares were withheld to cover tax obligations related to the vesting of restricted stock units for the CEO. It does not reflect a voluntary sale or purchase of shares in the open market, nor does it provide new information regarding the company's operational performance, financial health, or strategic direction. As such, it offers no basis for a change in investment thesis, and a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals rather than this specific insider filing.

Keywords

Orchestra BioMed Holdings, OBIO, Form 4, SEC Filing, Insider Transaction, David P Hochman, Restricted Stock Units, RSU Vesting, Tax Withholding, Executive Compensation, Beneficial Ownership